RINVOQ and DUPIXENT® (dupilumab) have different FDA-approved uses and safety profiles

RINVOQ

Once-daily pill (15 mg or 30 mg)

Use

For people 12+ years with moderate to severe eczema (atopic dermatitis) that did not respond to previous treatment and their eczema is not well controlled using other pills or injections, including biologics, or the use of other pills or injections is not recommended.

DUPIXENT

Injection

Use

For adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids.

DUPIXENT® is a registered trademark of Sanofi Biotechnology. See US Prescribing Information for further information.

RINVOQ has a BOXED WARNING to highlight serious safety risks. RINVOQ can cause serious side effects, including:

  • Serious infections
  • Cancer and immune system problems
  • Blood clots (thrombosis) 
  • Allergic reactions
  • Tears (perforation) in the stomach or intestines
  • Changes in certain laboratory test results
  • Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors. RINVOQ is a JAK inhibitor medicine.
  • Increased risk of major cardiovascular events, such as heart attack, stroke, or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called Janus kinase (JAK) inhibitors, especially if you are a current or past smoker.

DUPIXENT does not have a BOXED WARNING. DUPIXENT can cause serious side effects, including:

  • Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe.
  • Eye problems 
  • Inflammation of your blood vessels
  • Joint aches and pain

These are not all the side effects associated with either product. It is important to talk to your doctor about all the benefits and risks of each treatment option.

To understand more about the differences between each product’s safety profiles, please see full Important Safety Information for RINVOQ below and full Patient Information for DUPIXENT here

Results from a head-to-head trial of RINVOQ vs DUPIXENT

In this study, patients knew that RINVOQ or DUPIXENT was being used, which may have influenced the results. Overall conclusions comparing two active therapies cannot be made on a single clinical trial alone.

Study Design: One clinical study of 920 patients assessed RINVOQ and DUPIXENT for the treatment of moderate to severe eczema in patients aged 12-64 years who were not well controlled using other pills or injections, or the use of other pills or injections was not recommended. This study was not designed to make comparisons about safety.

Dosing Information: The approved starting dose for RINVOQ is 15 mg. For certain patients in the study, doctors increased the dose to 30 mg. Patients in the study took RINVOQ exactly as instructed. DUPIXENT was dosed per its label.

>2x as many people

achieved both little to no itch & 90% clearer skin with RINVOQ vs DUPIXENT at 16 weeks

Percentage of patients with little to no itch & 90% clearer skin at 16 weeks

Little to no itch at 4 weeks and 16 weeks

Percentage of patients with little to no itch at 4 weeks
Percentage of patients with little to no itch at 16 weeks

Skin clearance at 4 weeks and 16 weeks

Percentage of patients with itch & 90% clearer skin at 4 weeks
Percentage of patients with  90% clearer skin at 16 weeks

To understand more about the differences between each product’s safety profiles, please see full Important Safety Information for RINVOQ below and full Patient Information for DUPIXENT here

The itch and rash of eczema can be unrelenting. But RINVOQ is proven to help.

Not doing well on your current pill or injection, including biologics?

“Be an advocate for yourself. Let your doctor know if your eczema symptoms are still having a big impact.”

– Dr. Seminara, Dermatologist

SUGGESTED FOR YOU

Eczema is linked to an overactive immune system. RINVOQ works inside your body to help regulate it.

NEXT PAGE